The Other Agency: CMS Shocks Wall Street-and Amgen Takes a Hit

Biotech investors are used to worrying about what FDA will or won't do to a blockbuster drug, especially in the current climate of drug safety hysteria. But Wall Street didn't expect the federal Medicare agency to get into the act.

Michael McCaughan

The events of May 15 sound like an all-too familiar story for biotech investors. A negative regulatory decision causes a...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet